Edition:
United Kingdom

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

104.40USD
13 Sep 2019
Change (% chg)

$-0.57 (-0.54%)
Prev Close
$104.97
Open
$105.33
Day's High
$105.95
Day's Low
$104.30
Volume
211,126
Avg. Vol
236,957
52-wk High
$109.02
52-wk Low
$78.97

Latest Key Developments (Source: Significant Developments)

Quest Diagnostics Sets Quarterly Cash Dividend Of $0.53 Per Share
Tuesday, 14 May 2019 

May 14 (Reuters) - Quest Diagnostics Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.53PER SHARE.  Full Article

Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Quest Diagnostics Inc ::QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2019.Q4 REVENUES OF $1.84 BILLION, DOWN 1.4% VERSUS 2017.Q4 DILUTED EPS OF $0.92 ON A REPORTED BASIS.QTRLY ADJUSTED EARNINGS PER SHARE $1.36.SEES 2019 NET REVENUES OF $7.60 BILLION TO $7.75 BILLION.FULL YEAR 2019 REPORTED DILUTED EPS EXPECTED TO BE GREATER THAN $5.16.SEES 2019 ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION EXPENSE GREATER THAN $6.40.QUEST DIAGNOSTICS - SEES 2019 CAPEX $350 MILLION TO $400 MILLION.Q4 EARNINGS PER SHARE VIEW $1.37, REVENUE VIEW $1.88 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $6.56, REVENUE VIEW $7.76 BILLION -- REFINITIV IBES DATA.  Full Article

Clinical Genomics and Quest Diagnostics extend collaboration to provide Insure One
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Quest Diagnostics Inc ::CLINICAL GENOMICS AND QUEST DIAGNOSTICS EXTEND COLLABORATION TO PROVIDE INSURE ONE.CLINICAL GENOMICS SAYS 5-YEAR EXTENSION TO CO & QUEST'S U.S. SUPPLY AGREEMENT FOR INSURE ONE.  Full Article

Healthcare Global Enterprises Says Co's Associate To Buy India Medical Diagnostics Business Of Quest Diagnostics
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Healthcare Global Enterprises Ltd :STRAND LIFE SCIENCES SIGNED AGREEMENT TO ACQUIRE INDIA MEDICAL DIAGNOSTICS BUSINESS OF QUEST DIAGNOSTICS.SAYS COMPANIES AIM TO CLOSE SALE BY END OF Q1 OF CALENDAR YEAR 2019.  Full Article

Quest Diagnostics Q2 Adjusted Diluted EPS Excluding Amortization Of $1.75
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Quest Diagnostics Inc ::QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUES OF $1.92 BILLION, UP 3.0% FROM 2017.NARROWS OUTLOOK FOR FULL YEAR 2018 REVENUES AND DILUTED EPS.Q2 REPORTED DILUTED EPS OF $1.57.Q2 REPORTED DILUTED EPS OF $1.57.SEES FY ADJUSTED EARNINGS PER SHARE $6.53 TO $6.67 EXCLUDING ITEMS.Q2 ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION OF $1.75.Q2 EARNINGS PER SHARE VIEW $1.76, REVENUE VIEW $1.95 BILLION -- THOMSON REUTERS I/B/E/S.FULL YEAR 2018 REVENUES NOW EXPECTED TO BE BETWEEN $7.70 BILLION AND $7.74 BILLION.FY2018 EARNINGS PER SHARE VIEW $6.61, REVENUE VIEW $7.72 BILLION -- THOMSON REUTERS I/B/E/S.SEES FY 2018 CAPEX IN RANGE OF $350 MILLION - $400 MILLION.FY 2018 REPORTED DILUTED EPS NOW EXPECTED TO BE BETWEEN $5.50 AND $5.64.SEES FY 2018 REVENUE IN RANGE OF $7.70 BILLION - $7.74 BILLION.  Full Article

Genomic Vision Extends Its Collaboration With Quest Diagnostics​
Wednesday, 14 Mar 2018 

March 14 (Reuters) - GENOMIC VISION SA ::‍GENOMIC VISION EXTENDS ITS COLLABORATION WITH QUEST DIAGNOSTICS IN SPINAL MUSCULAR ATROPHY (SMA)​.‍IF SUCCESSFULLY, GENOMIC VISION WILL RECEIVE ROYALTIES FOR ANY TEST SERVICE INDEPENDENTLY DEVELOPED BY QUEST AS A RESULT OF RESEARCH​.  Full Article

Quest Diagnostics Reports Q4 Adjusted Earnings Per Share $1.40
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Quest Diagnostics Inc ::QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER.Q4 REVENUES OF $1.94 BILLION, UP 4.1% VERSUS 2016.SEES ‍FULL YEAR 2018 REPORTED DILUTED EPS $5.42 TO $5.62​.Q4 DILUTED EPS OF $1.82 ON A REPORTED BASIS.SEES ‍FULL YEAR 2018 ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION EXPENSE AND ETB $6.50 TO $6.70​.Q4 REVENUE VIEW $1.94 BILLION -- THOMSON REUTERS I/B/E/S.SEES ‍FULL YEAR 2018 REVENUES $7.70 BILLION TO $7.77 BILLION​.Q4 ADJUSTED EARNINGS PER SHARE $1.40.FY2018 REVENUE VIEW $7.91 BILLION -- THOMSON REUTERS I/B/E/S.SEES ‍FULL YEAR 2018 CAPITAL EXPENDITURES $350 MILLION TO $400 MILLION​.Q4 EARNINGS PER SHARE VIEW $1.38 -- THOMSON REUTERS I/B/E/S.‍IN 2018 COMPANY EXPECTS TO REALIZE APPROXIMATELY $180 MILLION IN TAX SAVINGS ON AN ADJUSTED BASIS​.‍BOARD OF DIRECTORS AUTHORIZED AN 11% INCREASE IN ITS QUARTERLY DIVIDEND FROM $0.45 TO $0.50 PER SHARE​.BOARD AUTHORIZED AN 11% INCREASE IN ITS QUARTERLY DIVIDEND TO $0.50 PER SHARE.  Full Article

Quest Diagnostics provides update on impact of 2018 Medicare payment rates
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Quest Diagnostics Inc ::Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests.Quest Diagnostics Inc - ‍expects impact of final fee schedule rates under Protecting Access To Medicare Act​ (PAMA) to be about 4% in 2018.Quest Diagnostics Inc - ‍expects impact of final fee schedule rates under PAMA to be about 10% in 2019 and 2020.  Full Article

FDA approves Clinical Genomics, Quest Diagnostics Insure One
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Quest Diagnostics Inc :Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™.Quest Diagnostics Inc- ‍insure One is expected to be commercially available in early 2018​.  Full Article

Quest Diagnostics acquires certain assets of California Laboratory Associates
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Quest Diagnostics Inc :Quest Diagnostics acquires California Laboratory Associates.Quest Diagnostics Inc - ‍financial terms of agreement were not disclosed.​.Quest Diagnostics Inc - ‍it has acquired certain assets of California Laboratory Associates, a clinical lab network​.  Full Article

RPT-EXCLUSIVE-Philips, under investigation in U.S. and Brazil, fired whistleblower who warned of graft

(Repeats for additional clients with no changes to text) By Brad Brooks SAO PAULO, August 21 Healthcare giant Philips was warned of suspicious sales of its medical equipment to the Brazilian government, and failed to halt them, nearly a decade before an alleged bribery racket was exposed in the company's Brazil operations last year, Reuters has learned. Claims of malfeasance reached the highest levels of the Dutch conglomerate as early as 2010, according to court records